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IgA nephropathy in Blacks: Studies of IgA2 allotypes and clinical
course. The prevalence of IgA nephropathy (IgAN) varies among racial
groups, being most common among Caucasians and Orientals and rare
in Blacks. Other investigators have hypothesized that the risk for IgAN
may be influenced by the IgA2 allotype. It has been suggested that the
rare Black patients with IgAN may be homozygous for the A2m(l)
allele which predominates in Whites, but is less common in Blacks. In
a multicenter study, 27 Black IgAN patients were enrolled to investi-
gate this hypothesis and analyze the clinical course of disease in Blacks.
The IgA2 allotypes of 18 Black patients and 14 controls were deter-
mined using restriction fragment length polymorphism analysis. Three
patients were homozygous for the A2m(l) allele, four were homozygous
for A2m(2) and 11 were heterozygous. The respective allelic frequen-
cies of A2m(l) and A2m(2) were 0.47 and 0.53 and did not differ
significantly from Black controls. Most clinical manifestations of dis-
ease did not significantly differ with respect to distribution of the two
alleles, although the gender ratio differed between the homozygous
A2m(l) and heterozygous patients. The presence of the A2m(l) allele
did not increase the risk for IgAN, and the presence of the A2m(2) allele
or homozygosity for this allele did not protect Blacks from the devel-
opment of IgAN.
IgA nephropathy (IgAN) or Berger's disease is recognized
worldwide as the most common primary glomerulonephritis in
many geographic regions as well as among various ethnic
groups [I]. However, a markedly lower prevalence of IgAN has
been reported among Blacks in the United States [2, 3] and the
disorder is virtually absent in African Blacks [4, 5]. This racial
difference in the prevalence of disease is independent of the
racial mixture of hospital admissions or the performance of
renal biopsies [21. It has been proposed that the low incidence
of IgAN among Blacks may be attributed to a structural
property of IgA2 [61.
IgA is comprised of two subclasses, IgAl and IgA2 [7]. IgAl
is by far the predominant isotype observed in immunofluores-
cence studies of mesangial deposits of patients with IgAN
[8—10]. However, some Black patients have been shown to also
display IgA2 in the glomerular mesangium [111. IgA2 is genet-
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ically polymorphic and exists as two allotypes, designated
A2m(1) and A2m(2). In the A2m(l) molecule heavy and light
chains are not connected by interchain disulfide bonds [12, 131
and this molecule, unlike its A2m(2) counterpart, is cleaved by
IgA protease produced by Bacteroides gin givalis, B. interme-
dius, and Clostridium ramosum [14, 15]. A2m(2) has interchain
disulfide linkages and is resistant to cleavage. The IgA2 allo-
types also exhibit racial differences in their frequencies. The
frequency of the A2m(1) allele is approximately 0.98 in Whites,
0.36 in American Blacks and 0.32 in African Blacks [16, 17]. A
previous report hypothesized that the stability of the A2m(2)
molecule inferred by the resistance to cleavage and the disulfide
bonding might influence mucosal defense and confer protection
against IgAN to the Black population [6]. In that study, one
Black patient with IgAN was homozygous for the A2m(1)
allotype. Based on this single patient it was speculated that
Black patients with IgAN would be homozygous for the A2m(l)
allotype and that homozygosity for the A2m(2) allele would
protect against the development of IgAN.
Restriction site polymorphisms in the protein coding region
and in the flanking regions of the a2 gene make it possible to
differentiate IgAl and each allele of IgA2 by Southern blot
hybridization [18]. This report describes the allotypes of 18
black IgAN patients as determined by restriction fragment
length polymorphisms (RFLP). The results of the allotyping
were correlated with renal immunohistologic findings and clin-
ical expression of disease. In addition, the clinical course of the
entire group of 27 patients was analyzed.
Methods
Patients and controls
All Black patients with IgAN who underwent renal biopsy
January 1980 to July 1990 at the University of Alabama Hospi-
tal, Childrens' Hospital of Alabama and Veterans Administra-
tion Hospital, Birmingham, Alabama, Veterans Administration
Hospital, LeBonheur Children's Medical Center and University
of Tennessee, Memphis, Tennessee, University of Kentucky
Medical Center, Lexington, Kentucky and in private nephrol-
ogy practices in Birmingham, Alabama, Lexington, Kentucky,
Chattanooga, Tennessee, Tupelo, Mississippi and Hickory,
North Carolina, USA were invited to enroll in a multicenter
IgAN clinical database at the University of Alabama at Bir-
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mingham. IgAN had been diagnosed according to the usual
clinical and histologic criteria, as previously described [191.
Twenty-nine patients were identified and 27 enrolled (Table 1).
Eighteen patients provided a blood sample for the IgA2 allotyp-
ing studies. The study was approved by the Institutional Re-
view Board for Human Use at UAB. All patients gave informed
written consent prior to enrollment.
Onset of clinical disease was assumed to be the date that the
first evidence of renal disease was documented: macroscopic
hematuria, microscopic hematuria (>5 red blood cells/high-
power field), or pathologic proteinuria (urinalysis with 1 + or
greater proteinuria or 24-hour proteinuria greater than 400 mg).
The criterion for hypertension was an untreated sitting diastolic
blood pressure greater than 90 mm Hg in adults, or a measure-
ment above the ninety-fifth percentile for age in a child, on three
occasions. Creatinine clearances for pre-pubertal children and
post-pubertal girls were calculated using the formula: creatinine
clearance (mllminil.73 m2) = 0.55 x height [cm])/serum creat-
mine concentration (S) (mg/dl) [20]. For post-pubertal boys
the formula was: creatinine clearance (mi/mini! .73 m2) = 0.70
x height [cmj)/Scr (mg/dl) [20]. For adults (age> 17 years) with
normal renal function or modest/moderate renal insufficiency,
creatinine clearances were estimated according to the formula:
creatinine clearance ml/min = (140 — age [yr])/S (mg/dl) x
(weight [kg]/72) (xO.85, if female) [21]. Creatinine clearances of
adults were referenced to 1.73 m2 body surface area [22]. Renal
insufficiency was defined as a creatinine clearance less than 70
mi/mm/i .73 m2. End-stage renal failure was defined as the need
for renal replacement therapy. The duration of clinical fol-
low-up was the interval between the date of clinical onset and
last clinic visit or the date of the start of renal replacement
therapy.
For analysis of a possible racial influence on the development
of renal insufficiency in IgAN, we compared the predicted age
at end-stage renal failure of the Black patients with that of the
210 White patients in the UAB database who had undergone
renal biopsy during the same time span as the Black patients.
We used the Kaplan-Meier estimate to calculate the predicted
age at end-stage renal failure of the White and Black patients,
grouped by race [23]. The ages of the patients rather than the
interval from apparent clinical onset to last clinical assessment
were used, because the discovery of renal disease was seren-
dipitous for many individuals in both racial groups. Individuals
with impaired renal function but not requiring renal replace-
ment therapy were considered as survivors in the calculation.
In this analysis, July 1, 1990 was considered the date of last
follow-up for all patients followed regularly (within two years)
or otherwise known to be alive and not requiring dialysis or
transplantation. For patients not seen by a physician within two
years, the date of last follow-up was used.
The control panel consisted of 14 healthy Alabama Blacks
with no history of kidney disease. The population consisted of
four females and 10 males with an average age of 28 14 years,
range 22 to 60.
IgA subclass-specific immunofluorescence of renal biopsy
specimens
When cryopreserved renal tissue was available, cryostat
sections were examined at UAB. Fluorescein isothiocyanate-
or tetramethylrhodamine isothiocyanate-labeled monoclonal
antibodies (donated by Drs. J. Radl and J.J. Haijman, TNO,
The Netherlands) were used to detect the presence of IgAl and
IgA2 in the kidney specimens.
DNA analysis
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized blood by density centrifugation, quick-frozen
in liquid nitrogen and stored at —70°C until the DNA isolation
was performed. High molecular weight DNA was extracted
from PBMC isolated from both patients and controls [24]. The
DNA was analyzed for IgAl and IgA2 allotypes by Southern
hybridization [25]. Briefly, 10 g of genomic DNA was digested
overnight with EcoRl plus Pstl enzymes and the restricted
fragments were separated on 0.8% agarose gels. The gels were
depurinated and neutralized before pressure blotting onto Im-
mobilon-N (Millipore, Bedford, Massachusetts, USA). A five-
minute exposure to ultraviolet light at 312 nm cross linked the
DNA fragments to the membranes. Hybridization was carried
out at 42°C using lx SSC, 0.1% SDS, lx Denhardt's solution
[24], 100 sg/ml sonicated and denatured salmon sperm DNA
and 10% dextran sulfate. The a2XP8 probe was radiolabeled to
a specific activity of approximately 1 x l0 CPM/1sg. Hybrid-
ization was accomplished by overnight incubation. Subse-
quently, the membranes were washed twice for 10 minutes with
2x SSC, 0.1% SDS at room temperature followed by two
stringent washes at 65°C for 30 minutes, The membranes were
autoradiographed for three days at —70°C.
Probe
The probe used to identify the al gene and both alleles of the
a2 gene was a 600 bp, Pstl, EcoRl fragment from the clone
s2XP8 (provided by Dr. T.H. Rabbitts, Medical Research
Centre, Cambridge, UK). The a2XP8 probe encompasses all of
the CH2 exon and half of the CH3 exon of the a2 gene. This
region of DNA covers an area of significant sequence homology
between the al and s2 genes, and the a2 probe therefore
hybridizes equally with the al and a2 constant region genes
[26]. The restriction enzymes EcoRl and Pstl cleave the al and
s2 genes, creating distinct fragments which can be detected by
radiolabeled a2XP8 [18]. All three genes possess Pstl sites in
the C3 exon. The al gene (but neither of the a2 alleles) has an
additional Pstl site in CH1, yielding a 1.2 kb fragment. The
A2m(l) allele is restricted in a site 5' of the CH1 exon and yields
a distinct fragment of 2.0 kb. The A2m(2) allele is cleaved by
both enzymes. EcoRl cleaves in the CH1 exon and Psi'l in the
CH3 exon, resulting in a fragment of 0.9kb [18]. The probe was
excised from the Ml 3-XP8 vector and radiolabeled with a-32P-
dCTP by random priming.
Statistical analysis
Clinical numerical parameters are expressed as mean
standard deviation. Differences between these parameters in
the subsets of patients were analyzed by Student's unpaired
t-test or Chi square, as appropriate. The Mantel-Haenszel (log
rank) test was used to compare the survival curves [23].
Significance was set at the 0.05 level.
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Table 1, Clinical data on the Black IgAN patients
Urinary Urinary Creatinine
Age at proteina at blood" at clearancec at Prednisone Follow-up
Subject
no.
diagnosis!
sex
IgA2
allotype
Mode of
Onset
diagnosis!
latestd
diagnosis!
latest'1
diagnosis!
latest" Hypertension
Rx
(months)
(years)
onset!biopsy
1 17!F A2m(1) preeclampsia 3.8!ESRD 30!ESRD 69!ESRD Yes 4!4
2 l8!F A2m(1) mic H, prot 3+!ESRD 100!ESRD 37!ESRD Yes 9!!
3 24!F A2m(1) Mac H 0!1.8 0!lOO 96!95 Yes 2!!
4 15!F A2m(2) mic H 0.3!3+ 20!3+ 119!103 No 5!!
5 26!M A2m(2) mic H 3.7!1,9 4+!l+ 92!96 Yes 8!5
6 27!M A2m(2) nephrotic NA!5.0 l0!0 55!25 Yes 2!2
7 49!F A2m(2) ESRD ESRD!ESRD ESRD!ESRD ESRD!ESRD Yes 0
8 l1!M A2m(1/2) nephrotic 5.4!20.0 2!4+ l51!75 Yes 175 15/7
9 12!M A2m(1!2) Mac H 0.5/0 l5!0 91/74 Yes 24!7
10 16!M A2m(1!2) mie H, prot 3+/3+ 10!2 128!47 Yes 10!10
11 18!M A2rn(1!2) Mac H, HTN 4+!ESRD 25IESRD 62!ESRD Yes 12!2
12 31!M A2m(1!2) Mac H, prot 2.1!4+ 3+!0 110/93 Yes 5!5
13 34!M A2m(1!2) mic H 3.5/2.5 3+!2 71!41 No 2/2
14 35!F A2m(1!2) nephrotic 7.9!0.2 25!ND 86!20 Yes 101 10!8
15 36!F A2m(1!2) HTN l.2!ESRD 5/ESRD 35IESRD Yes 2 l!1
16 43/M A2m(1/2) Mac H 0,6/0 5/0 104/84 No 4/4
17 49/M A2m(1!2) HTN ESRD/ESRD ESRD/ESRD ESRD!ESRD Yes 0
18 51/M A2m(l!2) Mac H 1.5!0 ND!0 86/60 Yes 6!6
19 6/M ND Mac H 0.2/0.1 4+!12 73!135 No 6 1/1
20 10/M ND Mac H 0.7!0 50!0 126/108 No 1!!
21 12/F ND nephrotic 4+!12.0 0!4+ 168/94 Yes 9 1!!
22 12/M ND Mac H 1.5!ESRD I00!ESRD 130!ESRD Yes 6 4/4
23 13/M ND Mac H 1.3/0.6 100/100 108/100 No 8 16/4
24 17!M ND prot 4.5/3+ 40/3+ 34!36 Yes 22!!
25 23!M ND mic H, prot 2+!2+ 2+!4+ 123!l21 No 2!2
26 24/M ND mic H 2.4/4+ 100/15 82!84 No 1!0
27 27/M ND prot 12.4/1+ 1+!0 89/74 Yes 5!5
Abbreviations are: Prot, proteinuria; mic H, microscopic hematuria; Mac H, macroscopic hematuria; HTN, hypertension; nephrotic, nephrotic
syndrome; ESRD, end-stage renal disease; Rx, treatment; ND, not done; NA, not available.
a As grams per day or concentration by dipstickb Number of red cells per high-power field or the hemoglobin concentration by dipstick
As mllmin!1.73 m2
'1At last follow-up or before transplantation
Results
Allotypes of IgA2
The RFLP analysis was performed on DNA samples obtained
from 18 Black IgAN patients and 14 Black healthy controls
(Table 1). In addition to the Black IgAN patients, DNA from
seven White patients with IgAN and 10 White healthy controls
was analyzed (data not shown), Six of the White patients and all
White controls were homozygous for the A2m(l) allele. The
frequencies of the A2m(1) and A2m(2) alleles of the black
patients were 0.47 and 0.53, respectively, and 0.54 and 0.46 in
the healthy Black controls. There were no significant differ-
ences in the frequencies of either allele between the Black
patients and Black controls.
When the patients were subgrouped according to IgA2 allo-
type, there were no significant differences in the age at clinical
onset, frequency of macroscopic hematuria in the clinical
course, or magnitude of proteinuria. However, there was a
higher proportion of females in the patients determined to be
homozygous for the A2m(1) allele than in the heterozygous
patients (Table 1). Creatinine clearance at the last visit did not
differ between these three subgroups. At the last follow-up, 11
of the 18 patients had renal insufficiency, six of whom had
reached end stage. Two of the three patients homozygous for
A2m(1) had end-stage renal failure; the third had a normal
creatinine clearance. Of the four patients homozygous for
A2m(2), two had normal creatinine clearance, one had end-
stage renal failure and the fourth had chronic renal insuffi-
ciency. Of the 11 heterozygous patients, three had end-stage
renal failure and four had chronic renal insufficiency.
The renal biopsy specimens from eight patients were stained
with IgA subclass-specific antibodies. Four patients showed
significant staining for IgA2 (although less intense than the
staining for IgAl). A trace amount of IgA2 was detected in the
biopsy specimen of two patients and no staining was detected
for two patients. Of the eight biopsy specimens stained, the
IgA2 allotypes of five patients were determined, The presence
of IgA2 in the glomeruli was not unique to patients of a specific
IgA2 allotype. Three of these five patients stained positive for
IgA2; one was homozygous A2m(1), one was homozygous
A2m(2), and the third was heterozygous for the IgA2 alleles.
Clinical findings
The total number of patients diagnosed with IgAN at the
participating medical centers in the interval from January 1980
to July 1990 could not be precisely determined because of
incomplete records. However, a minimum of 405 patients were
identified, 29 (7.2%) of whom were Black; 27 enrolled in the
clinical study. Table 1 summarizes the IgA2 allotypes of the
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patients, the renal manifestations at apparent clinical onset of
disease, and the clinical data at the time of renal biopsy and last
follow-up visit. The age at clinical onset was 24 13 years and
ranged from 6 to 51 years. Eight patients were older than 30
years at clinical onset. Nineteen of the 27 patients were male.
Nine patients had clinically recognized renal disease before age
17 years. The initial clinical manifestation was detected after
age 30 in five males and three females. At the time of renal
biopsy, eight patients had renal insufficiency. Significant pro-
teinuria was detected at the time of biopsy in 21 patients. Ten
patients had experienced at least one episode of macroscopic
hematuria before renal biopsy, six of whom had clinically
apparent renal disease before age 15.
Fourteen of the 20 patients without endstage renal failure
have been seen by a physician within the last 12 months. The
length of follow-up after clinical onset was 6.4 6.5 years,
(range 0.1 to 24 years) and the interval from renal biopsy to the
last clinic visit was 3.4 2.7 years for the 25 patients not
presenting at end stage. Eight patients remain normotensive
and seven of these have normal creatinine clearance. Four
patients had a urinalysis without proteinuria and red blood cells
at the last visit. Three had normal renal function; the fourth had
a creatinine clearance of 60 ml/min/l .73 m2. Two of the three
patients with normal renal function were normotensive. At the
time of the last clinic visit, 13 of the 27 patients had renal
insufficiency; three males and four females had reached end
stage. One boy reached end-stage renal insufficiency before age
17 years. The 19 patients with a normal creatinine clearance at
the time of renal biopsy have been followed 3.9 2.8 years
after biopsy. Five of the 13 patients with renal insufficiency at
the last visit had a normal creatinine clearance at the time of
renal biopsy 6.0 3.2 years earlier. One of the five reached end
stage four years after renal biopsy. Nevertheless, renal survival
in the 27 Black patients was not significantly less than that of
the 210 White patients biopsied during the same time interval at
the participating medical centers (Fig. 1). The 14 patients with
normal renal function at last visit have been followed for a
relatively short interval after renal biopsy, 3.2 2.4 years,
range 0.1 to 7 years. Ten had significant proteinuria.
During the period of observation, seven patients were treated
with prednisone. This therapy had been initiated at the discre-
tion of the personal nephrologist and was implemented prior to
enrollment of the patient into our multicenter database. The
prednisone was generally given on an alternate-day schedule
but the amounts varied greatly (not shown). The duration of
treatment was 44 68 months (range, 2 to 175 months). Six
patients had been started on treatment when the creatinine
clearance was normal. Four patients had maintained normal
creatinine clearances 3.3 2.9 years after biopsy. However,
one patient progressed to end-stage renal failure four years after
diagnosis during which he received prednisone for six months.
The creatinine clearance of another patient has decreased from
86 to 20 ml/min/l .73 m 101 months after biopsy; throughout
this interval she has received alternate-day prednisone. The
seventh patient had a creatinine clearance 35 ml/min/l .73 m at
the time of biopsy, received two months of prednisone therapy,
and progressed to end-stage renal failure one year after biopsy.
By contrast, 10 of 13 patients with a normal creatinine clearance
at the time of biopsy have maintained normal renal function
without prednisone therapy; three have progressed to chronic
renal insufficiency. The follow-up of treated patients maintain-
ing normal renal function (3.3 2.9 years) did not differ from
that of untreated patients (3.1 2.4 years; P > 0.4).
Eleven patients (9 males, 2 females) had at least one episode
of macroscopic hematuria during the course of the disease.
Only one patient developed the initial episode of macroscopic
hematuria after the diagnosis was established. Nine of the 10
patients with a history of macroscopic hematuria before renal
White
patients
Fig. 1. Predicted age at end-stage renal failure
calculated by the life table method for the patients
20 30 40 50 60 70 with IgAN, grouped by race. The two patient groups
Age at kidney death, years do not significantly differ at any age.
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biopsy had a normal creatinine clearance at diagnosis. Seven
patients have maintained normal renal function: five untreated
patients for 3.6 2.6 years and two receiving prednisone for 2.5
2.1 years. One patient with macroscopic hematuria and
normal creatinine clearance before renal biopsy progressed to
end stage four years after biopsy.
Discussion
Familial studies of IgAN suggest that genetic factors may
play a role in the pathogenesis or susceptibility to the disease
[19, 27]. Previous reports have focused on Caucasians and
Orientals because of the difficulty in identifying Black patients.
Although the disease is rare in the Black population [31, studies
of Black patients with IgAN allow for a unique examination of
the genetic factors which may predispose individuals to this
disease. The present series of 27 Black patients with IgAN
assembled from several medical centers in the southeastern
United States shows that many of the clinical features of renal
disease are similar to those of White patients. As for many
American White patients with IgAN, several adults were inci-
dentally discovered to have renal disease and therefore the age
of clinical onset cannot be precisely defined. Macroscopic
hematuria was most common among patients less than 15 years
of age at clinical onset and its frequency decreased rapidly with
increasing age. Macroscopic hematuria rarely began after the
diagnosis had been established. The 2.4:1 male to female ratio is
similar to the gender ratio in White patients [I] and contrasts
with the 1:5 gender ratio reported for six Black patients in
North Carolina [3].
The progressive clinical outcome of a significant portion of
the Blacks in this study agrees with the frequently adverse
course of IgAN described in White patients [281. Twenty-six
percent of the Black patients progressed to end-stage renal
disease within a mean follow-up of 6.4 6.5 years after
apparent clinical onset. Strikingly, five of the 19 patients with
normal creatinine clearance at diagnosis progressed to renal
insufficiency, including one to end stage after four years. The
relative risk for end-stage renal failure is greater for Blacks than
for age-matched Whites with several types of renal disease,
including glomerulonephritis [291. Whether this racial difference
in renal prognosis is genetically determined or acquired remains
controversial. Some investigators have postulated that the
higher prevalence of progressive renal disease reflects an in-
creased prevalence of hypertension [30]. However, the pre-
dicted age at end-stage renal failure in the 27 Black patients in
the present study did not significantly differ from that of the 210
White patients in our database who had undergone renal biopsy
during the same time interval.
Seven patients in this series received prednisone for treat-
ment of IgA nephropathy, which resulted in no obvious benefit
for the preservation of renal function. However, the small
number of patients and the wide range in prednisone dosages
preclude a meaningful assessment of the efficacy of prednisone
treatment of Black patients with IgAN.
There are numerous mechanisms by which IgA plays an
important role in mucosal immunity, depending on the type of
antigen involved 11311. The binding of IgA antibody to antigen
inhibits the inflammatory reaction because, unlike IgG and 1gM
antibodies of the same specificity, human IgA does not activate
complement with its potential tissue-damaging consequences
[32]. Thus, the IgA system mitigates inflammatory disorders
arising from continuous exposure to environmental antigens.
Specific IgAl and IgA2 antibodies display, especially after
immunization, characteristic distributions of activities to cer-
tain groups of antigens. Thus, protein antigens elicit mostly
IgAl responses, unlike polysaccharides which elicit predomi-
nantly IgA2 responses [33, 341. However, studies of the asso-
ciation of specific activities of IgA2 antibodies against different
types of antigens with respect to allotype have not been
performed. This finding may be relevant in IgAN because of the
speculation that IgA2 of A2m(2) allotype may protect Blacks
from IgAN [6] since, unlike IgA2 of A2m( 1) allotype, the heavy
and light chains of A2m(2) are covalently linked [13]. By
serologic testing it was shown that a Black patient with IgAN
was homozygous for the A2m(l) allele, leading to the specula-
tion that Black patients with IgAN would be homozygous for
A2m(l). Furthermore, homozygosity for the A2m(2) allele was
postulated to protect Blacks against the development of IgAN
[6], This hypothesis assumes that the lack of covalent bonding
between light and heavy chains in the A2m(1) allotype would
lead to a decreased ability to react with antigen due to an altered
antigen-binding site. However, this is unlikely. Antibody mol-
ecules with cleaved interchain (H-L) disulfide bonds preserve
their antigen-binding capacity and other effector functions due
to the strong noncovalent interactions between heavy and light
chains [35, 36] which dissociate only in the presence of agents
such as urea, guanidine, or hydrochloric acid. This property is
also true for the IgA2 A2m(l) allotype: dimers of H and L
chains can be dissociated only by such agents [12, 131.
Nevertheless, it is possible that the susceptibility of the
A2m( I) allotype to cleavage by IgA proteases may influence the
pathogenesis of IgAN. Clostridium species isolated from the
intestine produce a protease which cleaves IgAl and IgA2 of
the A2m(l) allotype [37, 381. The cleavage occurs in the CH1
domain and results in the release of monomeric Fab and Fc
fragments [151. The Fab fragments maintain antigen binding
ability [391, but are unable to induce agglutination of bacteria or
prevent bacterial adherence. The IgA proteases produced at
mucosal surfaces may cleave secretory IgA antibodies of un-
known specificity that protect against IgAN. The released
fragments would bind to relevent antigens, but be unable to
mediate their elimination. In addition, the binding of Fab
fragments to antigen could prevent the binding of intact anti-
bodies or block epitopes recognized by antibodies of other
isotypes [311. Thus, the A2m(2) allotype which is resistant to
cleavage and predominates in blacks may be protective against
IgAN.
We have determined the IgA2 allotypes of 18 Black IgAN
patients by RFLP analysis. Three of the patients were homozy-
gous for the A2m(l) allotype that predominates in Caucasians.
Four patients were homozygous for the A2m(2) allele and they
exhibited clinical manifestations similar to those of patients
with the A2m(l) allotype. Eleven patients were heterozygous
for the two IgA2 alleles. The IgA2 allelic frequencies in the
patient population were similar to those of the control group.
These results indicate that the A2m(2) allotype is neither
protective against IgAN nor can the A2m(l) allotype in Black
individuals serve as a marker for the disease. However, we
cannot exclude the possibility that expression of the A2m(2)
allele is altered in these patients. In a number of allotype
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systems in several species, quantitative levels of expression are
reflected by a pecking order", or unequal expression of the
different alleles [reviewed in 401. This pecking order of expres-
sion exists for the human Gm allotypes and might also influence
the expression of Am allotypes. Although unlikely, it is possible
that an alteration in the regulation of gene expression in the
heterozygous Black IgAN patients might enhance synthesis of
A2m(l)-positive IgA molecules and somehow predispose the
individuals to disease. The difficulty in obtaining allotype-
specific antibodies and establishing standards to quantitate the
levels of each allotype in sera limits the ability to test this
hypothesis.
The differences in the prevalence of IgAN among racial and
ethnic groups may reflect other genetically-determined influ-
ences in the pathogenesis of the disease [27]. Reports of familial
IgAN and the identification of families in which in vitro abnor-
malities of the IgA immune system were common support this
hypothesis [27]. Many of these families were Caucasian. At
present, the racial differences in the prevalence of IgAN have
not been explained by differences of the IgA immune system in
Whites and Blacks. In point of fact, in-depth investigations of
possible racial differences in the immune system have not been
pursued. It is possible that racial admixture of alleles of a yet
unknown gene may account for the apparently increased prev-
alence of IgAN in Blacks in the southeastern United States
compared with Blacks in west Africa. Indeed, racial admixture
accounts for the increased prevalence of insulin-dependent
diabetes in American Blacks compared with African Blacks
[41].
In summary, this multicenter study comprises the largest
reported series of Black patients with IgAN, and confirms
previous reports concerning the rarity of Blacks among patients
with IgAN. The manifestations of IgAN in Black patients were
similar to the clinical features of Whites. The frequencies of the
IgA2 allotypes in Black patients with IgAN were similar to
those of Black controls; thus, our results do not support the
hypothesis that IgA2 allotypes influence the development of
IgAN in Black patients.
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